



October 1, 2025

Company:	KYORIN Pharmaceutical Co., Ltd.
Representative:	Yutaka Ogihara Representative Director, President and CEO (Security Code: 4569, TSE Prime.)
Contact:	Shota Kikuchi Director, Corporate Planning
Telephone:	03-6374-9702

KYORIN and Hinge Bio Enter into a Collaboration and License Agreement of HB2198 in Japan for SLE and other diseases

KYORIN Pharmaceutical Co., Ltd. announced today that it has entered into an exclusive license agreement with Hinge Bio Inc. (BURLINGAME, CA, CEO : Harold E. “Barry” Selick, “Hinge Bio”) on September 30, 2025, for HB2198, new drug candidate for systemic lupus erythematosus (SLE), discovered by Hinge Bio.

Under the terms of this agreement, KYORIN has obtained the exclusive rights in Japan to develop and commercialize HB2198 for the treatment of SLE and other diseases. KYORIN will make an upfront payment of USD 10 million to Hinge Bio. Hinge Bio is also eligible to receive milestone payments of up to USD 95 million for the SLE indication upon the progress of development, approval and the achievement of certain net sales. For indications other than SLE, and separate payment will be made. In addition, royalties based on net sales will be provided to Hinge Bio, and KYORIN will bear a portion of the clinical development costs incurred by Hinge Bio.

Autoimmune diseases such as SLE are caused by an aberrant immune system that mistakenly identifies the body’s own tissues as foreign, leading to excessive immune responses that cause chronic inflammation and organ damage. Many patients cannot get their symptoms under control with existing treatments and suffer from conditions such as joint pain, skin problems, kidney damage, and central nervous system issues.

HB2198 is a humanized bispecific antibody discovered using Hinge Bio’s proprietary GEM-DIMER™ technology platform. It aims to “reset” the immune system by simultaneously targeting both CD19 and CD20 molecules on the surface of B cells, which play a major role in the development of autoimmune diseases, and by rapidly and deeply depleting B cells in both the circulating blood and lymphoid tissues. Preclinical in vivo studies have demonstrated HB2198’s deep and rapid B cell depletion activity, and it is expected to provide an excellent new treatment option for patients suffering from autoimmune diseases. A Phase 1 clinical trial for patients with SLE is currently being prepared in the United States.

KYORIN aims to create high-value new drugs that meet medical needs and has prioritized “Expand

development pipeline” under its medium-term business plan “Vision 110 –Stage1–”. With this agreement, we are committed to advancing the development of new treatment options for patients as soon as possible, contributing to people’s health.

The impact on the consolidated earnings forecast for the fiscal year ending March 2026 is expected to include the upfront payment to Hinge Bio under this agreement, which will be recorded as SG&A expenses (R&D expenses) for the current fiscal year.

[Reference]

About Hinge Bio Inc.

Hinge Bio, Inc. is a privately held development-stage biotechnology company leveraging its proprietary GEM-DIMER™ platform to design and develop the next generation of therapeutics leading to address the problems of inadequate efficacy, resistance, and side effects in the fields of autoimmunity, inflammatory disease, cancer, and other disease. The GEM-DIMER™ technology platform enables the creation of multivalent, multispecific antibody-based therapeutics that are designed to bind their targets cooperatively allowing for dramatically enhanced biological activity and unique functionality. Hinge Bio is advancing a pipeline of programs with an initial focus on autoimmune disease.

This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.